Vildagliptin for the treatment of diabetes

Therapy

Volumn 8, Issue 6, 2011, Pages 703-719

  Samraj, George P ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Dipeptidyl peptidase type 4 inhibitor; Gastric inhibitory peptide; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Incretins; Type 2 diabetes; Vildagliptin

Indexed keywords

ACARBOSE; ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCOSE; INCRETIN; INSULIN; LINAGLIPTIN; LIPID; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; WARFARIN;

ACUTE PANCREATITIS; ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLISTER; BRONCHITIS; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIABETES MELLITUS; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; GLUCAGON RELEASE; GLUCOSE METABOLISM; HEART DISEASE; HORMONE ACTION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFECTION; INFLUENZA; INSULIN RELEASE; INSULIN SENSITIVITY; LACTATION; LIPID METABOLISM; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PERIPHERAL EDEMA; PREGNANCY; REPRODUCTIVE TOXICITY; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DEFECT; SKIN DISEASE; SKIN EXFOLIATION; SKIN ULCER; THYROID DISEASE; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 81255199065     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.11.75     Document Type: Article

References (112)

1. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of Type
2. diabetes: preclinical biology and mechanisms of action. Diabet. Care 30, 1335-1343 (2007).
3. Bellary S. For Type 2 diabetes poorly controlled by metformin monotherapy, the addition of any non-insulin antidiabetic drug reduces HbA1c to a similar extent, but with differing effects on weight and hypoglycaemic risk. Evid. Based Med. 16, 39-40 (2011).
4. Mathieu C. The scientific evidence: vildagliptin and the benefits of islet enhancement. Diabet. Obes. Metab. 11(Suppl. 2), 9-17 (2009).
5. Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with Type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 3, 339 (2009).
6. Pantalone KM, Kattan MW, Yu C et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in Type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 46, 145-154 (2009).
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007). (Pubitemid 46919772)
8. Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol. Metab. Clin. 18, 163-183 (1989). (Pubitemid 19058108)
9. Zimmerman BR. Sulfonylureas. Endocrinol. Metab. Clin. North Am. 26, 511-521 (1997).
10. Inzucchi SE. Oral antihyperglycemia therapy for Type 2 diabetes: scientific review. JAMA 287, 360-372 (2002). (Pubitemid 34256388)
11. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 63, 492-498 (1986). (Pubitemid 16035703)
12. Knop FK, Vilsboøll T, Hoøjberg PV et al. Reduced incretin effect in Type 2 diabetes: cause or consequence of the diabetic state?. Diabetes 56, 1951-1959 (2007). (Pubitemid 47195814)
13. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J. Diabet. Invest. 1, 8-23 (2010).
14. Nicolaus M, Brodl J, Linke R, Woerle J, Goke B, Schirra J. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J. Clin. Endocrinol. Metab. 96(1), 229-236 (2011).
15. Seino Y. Understanding the incretin effect. J. Clin. Endocrinol. Metab. 96(4), 934-935 (2011).
16. Nielsen LL. Incretin mimetics and DPP-IV inhibitors for the treatment of Type 2 diabetes. Drug. Discov. Today 10(10), 703-710 (2005). (Pubitemid 40724552)
17. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45, 1111-1119 (2002). (Pubitemid 34985287)
18. Holst JJ. The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409-1439 (2007). (Pubitemid 350041474)
19. McIntosh CHS. Incretin-based therapies for Type 2 diabetes. Can. J. Diabet. 32(2), 131-139 (2008). (Pubitemid 351883878)
20. Kjems LL, Holst JJ, Vnlund A, Madsbad S. The influence of GLP-1 on glucosestimulated insulin secretion: effects on b-cell sensitivity in Type 2 and nondiabetic subjects. Diabetes 52(2), 380-386 (2003). (Pubitemid 36173193)
21. McIntosh CHS. Incretin-based therapies for Type 2 diabetes. Can. J. Diabet. 32(2), 131-139 (2008). (Pubitemid 351883878)
22. Lankas GR, Leiting B, Roy RS et al. Dipeptidyl peptidase IV inhibition for the treatment of Type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54(10), 2988-2994 (2005). (Pubitemid 41401097)
23. Villhauer EB, Brinkman JA, Naderi GB et al. 1-[[(3-hydroxy-1-adamantyl) amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 46, 2774-2789 (2003). (Pubitemid 36702545)
24. Henness S, Keam SJ. Vildagliptin. Drugs 66, 1989-2001 (2006). (Pubitemid 44771935)
25. Ahren B, Landin-Olsson M, Jansson PA et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in Type 2 diabetes. J. Clin. Endocrinol. Metab. 89(5), 2078-2084 (2004). (Pubitemid 38619835)
26. He YL, Balch A, Campestrini J et al. Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with Type 2 diabetes. Clin. Pharmacol. Ther. 77(2), 56 (2005).
27. He YL, Wang Y, Bullock JM. Pharmacodynamics of vildagliptin in patients with Type 2 diabetes during OGTT. J. Clin. Pharmacol. 47(5), 633-641 (2007). (Pubitemid 46632151)
28. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of Type 2 diabetes: a comparative review. Diabet. Obes. Metab. 13(1), 7-18 (2011).
29. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet. Med. 24, 955-961 (2007). (Pubitemid 47301637)
30. Hu P, Yin Q, Deckert F et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J. Clin. Pharmacol. 49, 39-49 (2009).
31. Sunkara G, Sabo R, Wang Y et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J. Clin. Pharmacol. 47(9), 1152-1158 (2007).
32. He YL, Sadler BM, Sabo R et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin. Pharmacokinet. 46(9), 787-802 (2007). (Pubitemid 47347450)
33. He YL, Sabo R, Campestrini J. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur. J. Clin. Pharmacol. 63(7), 677-686 (2007). (Pubitemid 46911348)
34. Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabet. Obes. Metab. 12(6), 495-509 (2010).
35. Schweizer A, Dickinson S, Ligueros-Saylan M. A new DPP-4 inhibitor for the treatment of Type 2 diabetes. Diabetologia. 52(Suppl. 1), S301 (2009) (Abstract).
36. He YL, Sabo R, Campestrini J et al. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br. J. Clin. Pharmacol. 65(3), 338-346 (2008). (Pubitemid 351316915)
37. He YL, Yamaguchi M, Ito H et al. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes. Int. J. Clin. Pharmacol. Ther. 48(9), 582-595 (2010).
38. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 45, 243-253 (1999). (Pubitemid 29408280)
39. Halimi S, Raccah D, Schweizer A, Dejager S. Role of vildagliptin in managing Type 2 diabetes mellitus in the elderly. Curr. Med. Res. Opin. 26(7), 1647-1656 (2010).
40. Schwartz SL. Treatment of elderly patients with Type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am. J. Geriatr. Pharmacother. 8(5), 405-418 (2010).
41. He H, Tran P, Yin H et al. Absorption, metabolism, and excretion of [14C] vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab. Dispos. 37(3), 536-544 (2009).
42. He YL, Sabo R, Riviere GJ et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr. Med. Res. Opin. 23(5), 1131-1138 (2007). (Pubitemid 46799597)
43. Serra D, He YL, Bullock J et al. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. Int. J. Clin. Pharmacol. Ther. 46(7), 349-364 (2008). (Pubitemid 352005928)
44. He YL, Sabo R, Picard F et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with Type 2 diabetes. Curr. Med. Res. Opin. 25(5), 1265-1272 (2009).
45. He YL, Ligueros-Saylan M, Sunkara G et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J. Clin. Pharmacol. 48(1), 85-95 (2008). (Pubitemid 350292271)
46. Ayalasomayajula SP, Dole K, He YL et al. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr. Med. Res. Opin. 23(12), 2913-2920 (2007).
47. Byrd JB, Touzin K, Sile S et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 51, 141-147 (2008). (Pubitemid 350307116)
48. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE-inhibitor-associated angioedema. Hypertension 54, 516-523 (2009).
49. Keating GM. Vildagliptin: a review of its use in Type 2 diabetes mellitus. Drugs 12, 70(16), 2089-2112 (2010).
50. Pratley RE, Jauffret-Kamel S, Galbreath E et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with Type 2 diabetes. Horm. Metab. Res. 38(6), 423-428 (2006). (Pubitemid 44047965)
51. Ristic S, Byiers S, Foley J et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with Type 2 diabetes: vildagliptin (LAF237) dose response. Diabet. Obes. Metab. 7(6), 692-698 (2005). (Pubitemid 41601073)
52. Ahren B, Schweizer A, Dejager S et al. Vildagliptin enhances islet responsiveness to both hyper-and hypoglycemia in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 94, 1236-1243 (2009).
53. Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of Action of the DPP-4 Inhibitor Vildagliptin in humans. Diab. Obes. Metab. 13(9), 775-783 (2011).
54. Scherbaum WA, Schweizer A, Mari A et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with Type 2 diabetes and mild hyperglycaemia. Diabet. Obes. Metab. 10, 1114-1124 (2008).
55. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment naive patients with Type 2 diabetes mellitus. Diabet. Obes. Metab. 11, 506-515 (2009).
56. Ahrén B, Gomis R, Standl E et al. Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with Type 2 diabetes. Diabet. Care 27 (12), 2874-2880 (2004). (Pubitemid 39565052)
57. Garber AJ, Schweizer A, Baron MA et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with Type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebocontrolled study. Diabet. Obes. Metab. 9(2), 166-174 (2007). (Pubitemid 46206560)
58. Rosenstock J, Kim SW, Baron MA et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with Type 2 diabetes. Diabet. Obes. Metab. 9 (2), 175-185 (2007). (Pubitemid 46206561)
59. Garber AJ, Foley JE, Banerji MA et al. Effects of vildagliptin on glucose control in patients with Type 2 diabetes inadequately controlled with a sulphonylurea. Diabet. Obes. Metab. 10(11), 1047-1056 (2008).
60. Kelley DE, Dunning BE, Ligueros-Saylan M et al. Four-week treatment with vildagliptin increases fasting plasma levels of intact incretin hormones both in patients with Type 1 (T1DM) and Type 2 (T2DM) diabetes. Diabetes 55(Suppl. 1) A344 (2006) (Abstract 1481-P).
61. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with Type 2 diabetes. Horm. Metab. Res. 38, 423-428 (2006). (Pubitemid 44047965)
62. Marfella R, Barbieri M, Grella R et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J. Diabet. Complicat. 24(2), 79-83 (2010).
63. Balas B, Baig MR, Watson C et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. 92, 1249-1255 (2007). (Pubitemid 46556394)
64. He YL, Bullock JM, Deacon CF et al. Pharmacodynamics of vildagliptin in patients with Type 2 diabetes during OGTT. J. Clin. Pharmacol. 47, 633-641 (2007). (Pubitemid 46632151)
65. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors diabetes, Obes. Metab. 12(8), 648-658 (2010).
66. Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabet. Metab. Syndr. Obes. 2, 117-126 (2009).
67. Azuma K, Radikova Z, Mancino J et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 93, 459-464 (2008). (Pubitemid 351240816)
68. Vardarli I, Nauck MA, Kothe LD et al. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "Isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 96(4), 945-954 (2011).
69. Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed b-cell function in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 90(8), 4888-4894 (2005). (Pubitemid 41159387)
70. Azuma K, Rádiková Z, Mancino J et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 93(2), 459-464 (2008). (Pubitemid 351240816)
71. He YL, Wang Y, Bullock JM. Pharmacodynamics of vildagliptin in patients with Type 2 diabetes during OGTT. J. Clin. Pharmacol. 47(5), 633-641 (2007). (Pubitemid 46632151)
72. Utzschneider KM, Tong J, Montgomery B et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves b-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabet. Care 31(1), 108-113 (2008).
73. Rosenstock J, Foley JE, Rendell M et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabet. Care 31(1), 30-35 (2008).
74. Foley JE, Ligueros-Saylan M, He YL et al. Effect of vildagliptin on glucagon concentration during meals in patients with Type 1 diabetes. Horm. Metab. Res. 40, 727-730 (2008).
75. El-Ouaghlidi A, Rehring E, Holst JJ et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J. Clin. Endocrinol. Metab. 92(11), 4165-4171 (2007). (Pubitemid 350074727)
76. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related b-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with Type 2 diabetes over 1 year. Diabet. Care 28, 1936-1940 (2005). (Pubitemid 41060966)
77. Ahrén B, Foley JE, Ferrannini E et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with Type 2 diabetes mellitus inadequately controlled with metformin monotherapy. Diabet. Care 33(4), 730-732 (2010).
78. D'Alessio DA, Denney AM, Hermiller LM et al. Treatment with the DPP-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with Type 2 diabetes. J. Clin. Endocrinol. Metab. 94, 81-88 (2008).
79. Matikainen N, Mänttäri SA, Schweizer Ulvestad A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with Type-2 diabetes. Diabetologia 49, 2049-2057 (2006). (Pubitemid 44168471)
80. Schweizer A, Couturier A, Foley JE et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with Type 2 diabetes. Diabet. Med. 24(9), 955-961 (2007). (Pubitemid 47301637)
81. Göke B, Hershon K, Kerr D et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with Type 2 diabetes: comparison with metformin. Horm. Metab. Res. 40(12), 892-895 (2008).
82. Bolli G, Dotta F, Rochotte E et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabet. Obes. Metab. 10(1), 82-90 (2008). (Pubitemid 350302434)
83. Boschmann M, Engeli S, Dobberstein K et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. 94, 846-852 (2009).
84. Pratley RE, Schweizer A, Rosenstock J et al. Robust improvements in fasting and prandial measures of b-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabet. Obes. Metab. 10, 931-938 (2008).
85. Greenbaum CJ, Mandrup-Poulsen T, McGee PF et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of b-cell function in therapeutic trials in Type 1 diabetes. Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Diabet. Care 31(10), 1966-1971 (2008).
86. Mari A, Scherbaum WA, Nilsson PM et al. Characterization of the influence of vildagliptin on model-assessed b-cell function in patients with Type 2 diabetes and mild hyperglycemia. J. Clin. Endocrinol. Metab. 93, 103-109 (2008).
87. Ristic S, Byiers S, Foley J et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with Type 2 diabetes: vildagliptin (LAF237) dose response. Diabet. Obes. Metab. 7(6), 692-698 (2005). (Pubitemid 41601073)
88. Dejager S, Razac S, Foley JE et al. Vildagliptin in drug-naive patients with Type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm. Metab. Res. 39(3), 218-223 (2007). (Pubitemid 46580622)
89. Kikuchi M, Abe N, Kato M et al. Vildagliptin dose-dependently improves glycemic control in Japanese patients with Type 2 diabetes mellitus. Diabet. Res. Clin. Pract. 83(2), 233-240 (2009).
90. Pi-Sunyer FX, Schweizer A, Mills D et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with Type 2 diabetes. Diabet. Res. Clin. Pract. 76(1), 132-138 (2007). (Pubitemid 46240373)
91. Kikuchi M, Abe N, Kato M et al. Vildagliptin dose-dependently improves glycemic control in Japanese patients with Type 2 diabetes mellitus. Diabet. Res. Clin. Pract. 83(2), 233-240 (2009).
92. Scherbaum WA, Schweizer A, Mari A et al. Efficacy and tolerability of vildagliptin in drug-naive patients with Type 2 diabetes and mild hyperglycaemia. Diabet. Obes. Metab. 10(8), 675-682 (2008). (Pubitemid 352044298)
93. Scherbaum WA, Schweizer A, Mari A et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with Type 2 diabetes and mild hyperglycaemia. Diabet. Obes. Metab. 10(11), 1114-1124 (2008).
94. Iwamoto Y, Kashiwagi A, Yamada N et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with Type 2 diabetes: a week, randomized, double-blind, active-controlled study. Diabet. Obes. Metab. 12(8), 700-708 (2010).
95. Rosenstock J, Baron MA, Dejager S. Comparison of vildagliptin and rosiglitazone monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet. Care 30 (2), 217-223 (2007). (Pubitemid 46198322)
96. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet. Obes. Metab. 11(8), 804-812 (2009).
97. Pan C, Yang W, Barona JP et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet. Med 25(4), 435-441 (2008). (Pubitemid 351490110)
98. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with Type 2 diabetes. Horm. Metab. Res. 41(12), 905-909 (2009).
99. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in Type 2 diabetes. Diabetologia 50(6), 1148-1155 (2007). (Pubitemid 46701545)
100. Blonde L, Dagogo-Jack S, Banerji MA et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial -a primary care, Type 2 diabetes study. Diabet. Obes. Metab. 11(10), 978-986 (2009).
101. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III Type 2 diabetes population. Diabet. Obes. Metab. 12(6), 485-494 (2010).
102. Schweizer A, Dejager S, Foley JE, Kothny W. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies vascular health and risk management. Vasc. Health Risk Manag. 7, 49-57 (2011).
103. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like Peptide-1-based therapies. Gastroenterology 141(1), 150-156 (2011).
104. Girgis CM, Champion BL. Vildagliptininduced acute pancreatitis. Endocr. Pract. 17(3), e48-e50 (2011).
105. Ayoub WA, Kumar AA, Naguib HS, Taylor HC. Exenatide-induced acute pancreatitis. Endocr. Pract. 16(1), 80-83 (2010).
106. Garg R, Chen W, Pendergrass M. Acute pancreatitis in Type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabet. Care 33, 2349-2354 (2010).
107. Leahy JL, Hirsch IB, Peterson KA, Schneider D. Targeting {b}-cell function early in the course of therapy for Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 95(9), 4206-4216 (2010).
108. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of Type 2 diabetes: a comparative review. Diabet. Obes. Metab. 13, 7-18 (2011).
109. Nauck MA. Incretin-based therapies for Type 2 diabetes mellitus: properties, functions, and clinical implications. Am. J. Med. 124(Suppl. 1), S3-S18 (2011).
110. Schwartz SL. Treatment of elderly patients with Type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am. J. Geriatr. Pharmacother. 8(5), 405-418 (2010).
111. Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet. Med. 27(3), 318-326 (2010).
112. Esposito K, Cozzolino D, Bellastella G, Maiorino MI, Chiodini P, Ceriello A, Giugliano D. Dipeptydil peptidase-4 inhibitors and HbA1c target of <7% in Type 2 diabetes: meta-analysis of randomized controlled trials. Diab. Obes. Metab. 13(7), 594-603 (2011).